← Back to Clinical Trials
Recruiting NCT05963126

Fetuin A as a Predictor of Deterioration of Renal Function in Hypertonic Patients

Trial Parameters

Condition Arterial Hypertension
Sponsor University Hospital Ostrava
Study Type OBSERVATIONAL
Phase N/A
Enrollment 200
Sex ALL
Min Age 18 Years
Max Age 100 Years
Start Date 2023-07-01
Completion 2025-12-31
Interventions
No intervention.

Brief Summary

Commonly used parameters (creatinine, estimated glomerular filtration rate, and urine albumin/creatinine ratio) for prediction of decline of renal function are sensitive for advanced kidney impairment. Modified human urine Fetuin A (urine Fetuin A) with specific modification in urine (Fetuin A) can earlier predict the progression of kidney disease in patients with diabetes. Studies evaluating urine Fetuin A in hypertonic patients are still lacking.

Eligibility Criteria

Inclusion Criteria: * Arterial hypertension treated by at least one antihypertensive agent Exclusion Criteria: * Diabetes mellitus of any type, defined as fasting glucose \>7,0 mmol/l or any glycemia \>11,0 mmol/l, or HbA1c\>48 mmol/mol * Decompensated arterial hypertension defined as office blood pressure \>180/110 mmHg or on Ambulatory Blood Pressure Monitoring (ABPM) * Patient with renal replacement therapy * Present rheumatoid disease (rheumatoid arthritis, systemic lupus, sclerodermia, dermatomyositis, Inflammatory Bowel Disease, etc.), positivity of antinuclear antibody (ANA) / extractable nuclear antigen (ENA) screening * Acute infection defined as C-Reactive Protein (CRP) \>50 mg/l * Severe impairment of liver function defined as cirrhosis, Alanine Transaminase or ASpartate Transferase (ALT or AST) \>10 µkat/l * Terminal incurable illness

Related Trials